Riskpilot← Back to searchSign inGet full accessTheravision AB
ABActiveOrg 5593359903Rotevägen 19Computer programming activities · NACE 6210Est. 20210 employees
Revenue 2025
SEK 373K
-46% vs 2024
EBITDA margin
74.6%
-50% vs 2024
Equity ratio
61.5%
Financial strength
Net profit 2025
SEK 219K
-50% vs 2024
| Revenue | SEK 373K | -46% |
| EBITDA | SEK 278K | -50% |
| Net profit | SEK 219K | -50% |
| Total assets | SEK 462K | -25% |
| Equity | SEK 284K | -39% |
| Employees | 0 | — |
Legal name
Theravision AB
Org number
5593359903
Legal form
Aktiebolag
NACE code
6210 · Computer programming activities
Founded
21 september 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget skall bedriva utveckling och försäljning av datorprogram som genererar medicinska bilder med hög bildkvalité samt datorprogram som för läkare och annan sjukhuspersonal förenklar kvantifiering i medicinska bilder. I anslutning till detta kommer konsultverksamhet att bedrivas.
Address
Rotevägen 19
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 142 | 350 | 688 | 373 |
| Staff expenses | −20 | −10 | −25 | −77 |
| EBITDA | 117 | 242 | 557 | 278 |
| Depreciation & amort. | — | — | — | — |
| EBIT | 117 | 242 | 557 | 278 |
| Net financials | — | 1 | 2 | −0 |
| Profit before tax | 117 | 243 | 559 | 278 |
| Tax | −25 | −51 | −120 | −59 |
| Net profit | 92 | 193 | 439 | 219 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 142 | 296 | 612 | 462 |
| Equity | 117 | 220 | 465 | 284 |
| Long-term debt | — | — | — | — |
| Short-term debt | 25 | 75 | 147 | 177 |
| Total debt | 25 | 75 | 147 | 177 |
EBITDA margin
74.6%
This company
15.8%
Market median
+372% vs market
20222025
Equity ratio
61.5%
This company
38.2%
Market median
+61% vs market
20222025
Return on equity
77.1%
This company
18.4%
Market median
+319% vs market
20222025
Net profit margin
58.7%
This company
8.1%
Market median
+625% vs market
20222025
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20222025
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-21 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2026 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Theravision AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fred Peter Bernhardt | Chief Executive Officer | 0 companies |
| Fred Jonathan Bernhardt | Deputy Board Member | 0 companies |
| Isabelle Linnea Rydén | Deputy Board Member | 0 companies |
| Tobias Gabriel Rydén | Chairman | 0 companies |